Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer
Status:
Active, not recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to improve the loco-regional control rate and overall survival of
locally advanced head and neck squamous carcinoma (HNSCC). The investigators hypothesize that
the addition of nimotuzumab (a recombinant humanized murine immune antibody that blocks both
epidermal growth factor (EGF) and transforming growth factor (TGF)) to the current gold
standard of concurrent chemoradiotherapy (CCRT) (7)(8), an adjuvant setting in patients after
resection of their locally advanced HNSCC will confer therapeutic advantage.
Phase:
Phase 3
Details
Lead Sponsor:
National Cancer Centre, Singapore
Collaborators:
Innogene Kalbiotech Pte. Ltd National Medical Research Council (NMRC), Singapore